BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Dec. 14, 2005--Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Azad Pharma AG, located in Toffen Switzerland, to develop and supply three ANDA injectable drug products for critical care medicine. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Azad.
